- Home
- WVE vs NIC Comparison
WVE vs NIC Comparison
Compare WVE & NIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- NIC
- Stock Information
- Founded
- WVE 2012
- NIC 2000
- Country
- WVE Singapore
- NIC United States
- Employees
- WVE N/A
- NIC N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- NIC Major Banks
- Sector
- WVE Health Care
- NIC Finance
- Exchange
- WVE Nasdaq
- NIC Nasdaq
- Market Cap
- WVE 939.3M
- NIC N/A
- IPO Year
- WVE 2015
- NIC N/A
- Fundamental
- Price
- WVE $6.54
- NIC $121.27
- Analyst Decision
- WVE Strong Buy
- NIC Buy
- Analyst Count
- WVE 11
- NIC 4
- Target Price
- WVE $20.91
- NIC $119.25
- AVG Volume (30 Days)
- WVE 1.7M
- NIC 52.1K
- Earning Date
- WVE 05-08-2025
- NIC 04-15-2025
- Dividend Yield
- WVE N/A
- NIC 0.92%
- EPS Growth
- WVE N/A
- NIC 28.66
- EPS
- WVE N/A
- NIC 8.31
- Revenue
- WVE $104,939,000.00
- NIC $352,932,000.00
- Revenue This Year
- WVE N/A
- NIC N/A
- Revenue Next Year
- WVE N/A
- NIC $4.08
- P/E Ratio
- WVE N/A
- NIC $14.68
- Revenue Growth
- WVE N/A
- NIC 9.54
- 52 Week Low
- WVE $4.25
- NIC $76.01
- 52 Week High
- WVE $16.74
- NIC $121.91
- Technical
- Relative Strength Index (RSI)
- WVE 42.23
- NIC 65.94
- Support Level
- WVE $6.30
- NIC $118.53
- Resistance Level
- WVE $8.39
- NIC $121.91
- Average True Range (ATR)
- WVE 0.66
- NIC 2.58
- MACD
- WVE 0.10
- NIC 0.80
- Stochastic Oscillator
- WVE 33.21
- NIC 94.33
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.